KHKohei Hanaoka

Kohei Hanaoka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kohei Hanaoka has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Registration accuracy with the low dose kilovoltage cone-beam CT: A phantom study

    by Yoshiki Takei, Hajime Monzen, Kenji Matsumoto, Kohei Hanaoka, Mikoto Tamura, Yasumasa Nishimura

    The aim of this study was to investigate low-dose kilovoltage cone-beam CT (kV-CBCT) for image-guided radiotherapy, with a particular focus on the accuracy of image registration with low-dose protocols. Imaging doses were measured with a NOMEX semiconductor detector positioned at the front of head, thorax, and pelvis human body phantoms while kV-CBCT scans were acquired at different tube currents. Aspects of image quality (spatial resolution, noise, uniformity, contrast, geometric distortion, and Hounsfield unit sensitivity) and image registration accuracy using bone and soft tissue were evaluated. With preset and the lowest tube currents, the imaging doses were 0.16 and 0.08 mGy, 5.29 and 2.80 mGy, and 18.23 and 2.69 mGy for head, thorax, and pelvis, respectively. Noise was the only quality aspect directly dependent on tube current, being increased by 1.5 times with a tube current half that of the preset in head and thorax, and by 2.2 times with a tube current 1/8 of the preset in the pelvis. Accurate auto-bone matching was performed within 1 mm at the lowest tube current. The auto-soft tissue matching could not be performed with the lowest tube current; however, manual-soft tissue matching could still be performed within 2 mm or less. Noise was the only image quality aspect dependent on the imaging dose. Auto-bone and manual-soft tissue matching could still be performed at the lowest imaging dose. When optimizing kV-CBCT imaging dose, the impact on bone and soft tissue image registration accuracy should be evaluated.


  • Open Access

    Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma

    by Kohei Hanaoka, Makoto Hosono, Yoichi Tatsumi, Kazunari Ishii, Sung-Woon Im, Norio Tsuchiya, Kenta Sakaguchi, Itaru Matsumura

    Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of 18F-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receiving 90Y-ibritumomab tiuxetan (Zevalin®) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin’s B-cell lymphoma who underwent 90Y-ibritumomab tiuxetan therapy along with 111In-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of 111In-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and 111In-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of 111In-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in 111In-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while 111In-ibritumomab tiuxetan demonstrated skewness of 0.58 ± 0.16 and 0.73 ± 0.24 (p < 0.05), kurtosis of 2.39 ± 0.32 and 2.78 ± 0.53 (p < 0.02), and AUC-CSH of 0.37 ± 0.04 and 0.34 ± 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in 90Y-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of 111In-ibritumomab tiuxetan was correlated with the tumor response.


  • Measurements for a Contamination Control of a 223Ra Medicament

    by Sin-Ya Hohara, Makoto Hosono, Masayo Inagaki, Sung-Woon Im, Hideo Morimoto, Kohei Hanaoka, Kenta Sakaguchi, Hirokuni Yamanishi, Tetsuo Itoh